Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis.

Liu S, González Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, van Dinther M, Bos E, Zhang X, Le Dévédec SE, van de Water B, Koning RI, Zhu HJ, Mesker WE, Vertegaal A, Ovaa H, Zhang L, Martens JWM, Ten Dijke P.

Clin Cancer Res. 2019 Dec 19. pii: clincanres.1373.2019. doi: 10.1158/1078-0432.CCR-19-1373. [Epub ahead of print]

PMID:
31857432
2.

Total chemical synthesis of murine ISG15 and an activity-based probe with physiological binding properties.

Xin BT, Gan J, Fernandez DJ, Knobeloch KP, Geurink PP, Ovaa H.

Org Biomol Chem. 2019 Dec 28;17(48):10148-10152. doi: 10.1039/c9ob02127b. Epub 2019 Nov 11.

PMID:
31710063
3.

Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening.

Resnick E, Bradley A, Gan J, Douangamath A, Krojer T, Sethi R, Geurink PP, Aimon A, Amitai G, Bellini D, Bennett J, Fairhead M, Fedorov O, Gabizon R, Gan J, Guo J, Plotnikov A, Reznik N, Ruda GF, Díaz-Sáez L, Straub VM, Szommer T, Velupillai S, Zaidman D, Zhang Y, Coker AR, Dowson CG, Barr HM, Wang C, Huber KVM, Brennan PE, Ovaa H, von Delft F, London N.

J Am Chem Soc. 2019 Jun 5;141(22):8951-8968. doi: 10.1021/jacs.9b02822. Epub 2019 May 22.

4.

Profiling DUBs and Ubl-specific proteases with activity-based probes.

Geurink PP, van der Heden van Noort GJ, Mulder MPC, Knaap RCM, Kikkert M, Ovaa H.

Methods Enzymol. 2019;618:357-387. doi: 10.1016/bs.mie.2018.12.037. Epub 2019 Feb 14.

PMID:
30850060
5.

Kinetic analysis of multistep USP7 mechanism shows critical role for target protein in activity.

Kim RQ, Geurink PP, Mulder MPC, Fish A, Ekkebus R, El Oualid F, van Dijk WJ, van Dalen D, Ovaa H, van Ingen H, Sixma TK.

Nat Commun. 2019 Jan 16;10(1):231. doi: 10.1038/s41467-018-08231-5.

6.

A MALDI-TOF Approach to Ubiquitin Ligase Activity.

van Tol BDM, Geurink PP, Ovaa H.

Cell Chem Biol. 2018 Sep 20;25(9):1053-1055. doi: 10.1016/j.chembiol.2018.09.002.

7.

Native chemical ligation at methionine bioisostere norleucine allows for N-terminal chemical protein ligation.

Xin BT, van Tol BDM, Ovaa H, Geurink PP.

Org Biomol Chem. 2018 Aug 29;16(34):6306-6315. doi: 10.1039/c8ob01627e.

PMID:
30117511
8.

Irreversible inactivation of ISG15 by a viral leader protease enables alternative infection detection strategies.

Swatek KN, Aumayr M, Pruneda JN, Visser LJ, Berryman S, Kueck AF, Geurink PP, Ovaa H, van Kuppeveld FJM, Tuthill TJ, Skern T, Komander D.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2371-2376. doi: 10.1073/pnas.1710617115. Epub 2018 Feb 20.

9.

Inhibition of the Deubiquitinase Usp14 Diminishes Direct MHC Class I Antigen Presentation.

Palmer AL, de Jong A, Leestemaker Y, Geurink PP, Wijdeven RH, Ovaa H, Dolan BP.

J Immunol. 2018 Feb 1;200(3):928-936. doi: 10.4049/jimmunol.1700273. Epub 2017 Dec 27.

10.

A Fluorescence Polarization Activity-Based Protein Profiling Assay in the Discovery of Potent, Selective Inhibitors for Human Nonlysosomal Glucosylceramidase.

Lahav D, Liu B, van den Berg RJBHN, van den Nieuwendijk AMCH, Wennekes T, Ghisaidoobe AT, Breen I, Ferraz MJ, Kuo CL, Wu L, Geurink PP, Ovaa H, van der Marel GA, van der Stelt M, Boot RG, Davies GJ, Aerts JMFG, Overkleeft HS.

J Am Chem Soc. 2017 Oct 11;139(40):14192-14197. doi: 10.1021/jacs.7b07352. Epub 2017 Sep 29.

11.

Structural basis of the specificity of USP18 toward ISG15.

Basters A, Geurink PP, Röcker A, Witting KF, Tadayon R, Hess S, Semrau MS, Storici P, Ovaa H, Knobeloch KP, Fritz G.

Nat Struct Mol Biol. 2017 Mar;24(3):270-278. doi: 10.1038/nsmb.3371. Epub 2017 Feb 6.

12.

Activity-Dependent Photoaffinity Labeling of Metalloproteases.

Prely L, Klein T, Geurink PP, Paal K, Overkleeft HS, Bischoff R.

Methods Mol Biol. 2017;1491:103-111.

PMID:
27778284
13.

Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne.

Mevissen TET, Kulathu Y, Mulder MPC, Geurink PP, Maslen SL, Gersch M, Elliott PR, Burke JE, van Tol BDM, Akutsu M, Oualid FE, Kawasaki M, Freund SMV, Ovaa H, Komander D.

Nature. 2016 Oct 20;538(7625):402-405. doi: 10.1038/nature19836. Epub 2016 Oct 12.

14.

The Molecular Basis for Ubiquitin and Ubiquitin-like Specificities in Bacterial Effector Proteases.

Pruneda JN, Durkin CH, Geurink PP, Ovaa H, Santhanam B, Holden DW, Komander D.

Mol Cell. 2016 Jul 21;63(2):261-276. doi: 10.1016/j.molcel.2016.06.015. Epub 2016 Jul 14.

15.

Non-hydrolyzable Diubiquitin Probes Reveal Linkage-Specific Reactivity of Deubiquitylating Enzymes Mediated by S2 Pockets.

Flierman D, van der Heden van Noort GJ, Ekkebus R, Geurink PP, Mevissen TE, Hospenthal MK, Komander D, Ovaa H.

Cell Chem Biol. 2016 Apr 21;23(4):472-82. doi: 10.1016/j.chembiol.2016.03.009. Epub 2016 Apr 7.

16.

Development of Diubiquitin-Based FRET Probes To Quantify Ubiquitin Linkage Specificity of Deubiquitinating Enzymes.

Geurink PP, van Tol BD, van Dalen D, Brundel PJ, Mevissen TE, Pruneda JN, Elliott PR, van Tilburg GB, Komander D, Ovaa H.

Chembiochem. 2016 May 3;17(9):816-20. doi: 10.1002/cbic.201600017. Epub 2016 Mar 21.

17.

Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition.

Banno A, Garcia DA, van Baarsel ED, Metz PJ, Fisch K, Widjaja CE, Kim SH, Lopez J, Chang AN, Geurink PP, Florea BI, Overkleeft HS, Ovaa H, Bui JD, Yang J, Chang JT.

Oncotarget. 2016 Apr 19;7(16):21527-41. doi: 10.18632/oncotarget.7596.

18.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.

Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23.

19.

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.

Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Silzle T, Shabaneh TB, van der Linden WA, de Bruin G, Haile SR, van Rooden E, Appenzeller C, Li N, Kisselev AF, Overkleeft H, Driessen C.

Haematologica. 2015 Oct;100(10):1350-60. doi: 10.3324/haematol.2014.109421. Epub 2015 Jun 11.

20.

Catching a DUB in the act: novel ubiquitin-based active site directed probes.

Ekkebus R, Flierman D, Geurink PP, Ovaa H.

Curr Opin Chem Biol. 2014 Dec;23:63-70. Review.

PMID:
25461387
21.

Molecular characterization of ubiquitin-specific protease 18 reveals substrate specificity for interferon-stimulated gene 15.

Basters A, Geurink PP, El Oualid F, Ketscher L, Casutt MS, Krause E, Ovaa H, Knobeloch KP, Fritz G.

FEBS J. 2014 Apr;281(7):1918-28. doi: 10.1111/febs.12754. Epub 2014 Mar 3.

22.

OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis.

Mevissen TE, Hospenthal MK, Geurink PP, Elliott PR, Akutsu M, Arnaudo N, Ekkebus R, Kulathu Y, Wauer T, El Oualid F, Freund SM, Ovaa H, Komander D.

Cell. 2013 Jul 3;154(1):169-84. doi: 10.1016/j.cell.2013.05.046.

23.

On terminal alkynes that can react with active-site cysteine nucleophiles in proteases.

Ekkebus R, van Kasteren SI, Kulathu Y, Scholten A, Berlin I, Geurink PP, de Jong A, Goerdayal S, Neefjes J, Heck AJ, Komander D, Ovaa H.

J Am Chem Soc. 2013 Feb 27;135(8):2867-70. doi: 10.1021/ja309802n. Epub 2013 Feb 15.

24.

Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.

Geurink PP, van der Linden WA, Mirabella AC, Gallastegui N, de Bruin G, Blom AE, Voges MJ, Mock ED, Florea BI, van der Marel GA, Driessen C, van der Stelt M, Groll M, Overkleeft HS, Kisselev AF.

J Med Chem. 2013 Feb 14;56(3):1262-75. doi: 10.1021/jm3016987. Epub 2013 Jan 28.

25.

Identification and isolation of lantibiotics from culture: a bioorthogonal chemistry approach.

Li J, Girard G, Florea BI, Geurink PP, Li N, van der Marel GA, Overhand M, Overkleeft HS, van Wezel GP.

Org Biomol Chem. 2012 Nov 21;10(43):8677-83. doi: 10.1039/c2ob26050f.

PMID:
23033043
26.

A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents.

Geurink PP, El Oualid F, Jonker A, Hameed DS, Ovaa H.

Chembiochem. 2012 Jan 23;13(2):293-7. doi: 10.1002/cbic.201100706. Epub 2011 Dec 23. No abstract available.

27.

The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types.

Faesen AC, Luna-Vargas MP, Geurink PP, Clerici M, Merkx R, van Dijk WJ, Hameed DS, El Oualid F, Ovaa H, Sixma TK.

Chem Biol. 2011 Dec 23;18(12):1550-61. doi: 10.1016/j.chembiol.2011.10.017.

28.

Photoaffinity labeling in activity-based protein profiling.

Geurink PP, Prely LM, van der Marel GA, Bischoff R, Overkleeft HS.

Top Curr Chem. 2012;324:85-113. doi: 10.1007/128_2011_286. Review.

PMID:
22028098
29.

Activity-based profiling of 2-oxoglutarate oxygenases.

Geurink PP, Florea BI, Overkleeft HS.

Chem Biol. 2011 May 27;18(5):557-9. doi: 10.1016/j.chembiol.2011.05.002.

30.

Probing the proteasome cavity in three steps: bio-orthogonal photo-reactive suicide substrates.

Geurink PP, Florea BI, Van der Marel GA, Kessler BM, Overkleeft HS.

Chem Commun (Camb). 2010 Dec 21;46(47):9052-4. doi: 10.1039/c0cc03322g. Epub 2010 Oct 27.

PMID:
20981375
31.

Nature of pharmacophore influences active site specificity of proteasome inhibitors.

Screen M, Britton M, Downey SL, Verdoes M, Voges MJ, Blom AE, Geurink PP, Risseeuw MD, Florea BI, van der Linden WA, Pletnev AA, Overkleeft HS, Kisselev AF.

J Biol Chem. 2010 Dec 17;285(51):40125-34. doi: 10.1074/jbc.M110.160606. Epub 2010 Oct 11.

32.

Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t.

Florea BI, Verdoes M, Li N, van der Linden WA, Geurink PP, van den Elst H, Hofmann T, de Ru A, van Veelen PA, Tanaka K, Sasaki K, Murata S, den Dulk H, Brouwer J, Ossendorp FA, Kisselev AF, Overkleeft HS.

Chem Biol. 2010 Aug 27;17(8):795-801. doi: 10.1016/j.chembiol.2010.05.027.

33.

A cleavable linker based on the levulinoyl ester for activity-based protein profiling.

Geurink PP, Florea BI, Li N, Witte MD, Verasdonck J, Kuo CL, van der Marel GA, Overkleeft HS.

Angew Chem Int Ed Engl. 2010 Sep 10;49(38):6802-5. doi: 10.1002/anie.201001767. No abstract available.

PMID:
20715027
34.

Proteasome selectivity towards Michael acceptor containing oligopeptide-based inhibitors.

van der Linden WA, Geurink PP, Oskam C, van der Marel GA, Florea BI, Overkleeft HS.

Org Biomol Chem. 2010 Apr 21;8(8):1885-93. doi: 10.1039/b924134e.

PMID:
20449494
35.

Incorporation of fluorinated phenylalanine generates highly specific inhibitor of proteasome's chymotrypsin-like sites.

Geurink PP, Liu N, Spaans MP, Downey SL, van den Nieuwendijk AM, van der Marel GA, Kisselev AF, Florea BI, Overkleeft HS.

J Med Chem. 2010 Mar 11;53(5):2319-23. doi: 10.1021/jm9015685.

36.

Poly(ethylene glycol)-based stable isotope labeling reagents for the quantitative analysis of low molecular weight metabolites by LC-MS.

Abello N, Geurink PP, van der Toorn M, van Oosterhout AJ, Lugtenburg J, van der Marel GA, Kerstjens HA, Postma DS, Overkleeft HS, Bischoff R.

Anal Chem. 2008 Dec 1;80(23):9171-80. doi: 10.1021/ac801215c.

PMID:
18954088
37.

Solid-phase synthesis of succinylhydroxamate peptides: functionalized matrix metalloproteinase inhibitors.

Leeuwenburgh MA, Geurink PP, Klein T, Kauffman HF, van der Marel GA, Bischoff R, Overkleeft HS.

Org Lett. 2006 Apr 13;8(8):1705-8.

PMID:
16597146

Supplemental Content

Loading ...
Support Center